Please use this identifier to cite or link to this item: https://doi.org/10.1089/thy.2018.0664
Title: Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
Authors: Sinha, Rohit A 
Bruinstroop, Eveline 
Singh, Brijesh K 
Yen, Paul M 
Keywords: Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
thyroid hormone
metabolites
analogs
NAFLD
cholesterol
RECEPTOR-BETA AGONISTS
GENE-EXPRESSION
BINDING PROTEIN
MESSENGER-RNA
LDL RECEPTOR
BODY-WEIGHT
HEPATIC FAT
TRIIODOTHYROACETIC ACID
CHOLESTEROL-METABOLISM
REDUCES CHOLESTEROL
Issue Date: 1-Sep-2019
Publisher: MARY ANN LIEBERT, INC
Citation: Sinha, Rohit A, Bruinstroop, Eveline, Singh, Brijesh K, Yen, Paul M (2019-09-01). Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. THYROID 29 (9) : 1173-1191. ScholarBank@NUS Repository. https://doi.org/10.1089/thy.2018.0664
Abstract: Background: Thyroid hormones (THs) exert a strong influence on mammalian lipid metabolism at the systemic and hepatic levels by virtue of their roles in regulating circulating lipoprotein, triglyceride (TAG), and cholesterol levels, as well as hepatic TAG storage and metabolism. These effects are mediated by intricate sensing and feedback systems that function at the physiological, metabolic, molecular, and transcriptional levels in the liver. Dysfunction in the pathways involved in lipid metabolism disrupts hepatic lipid homeostasis and contributes to the pathogenesis of metabolic diseases, such as nonalcoholic fatty liver disease (NAFLD) and hypercholesterolemia. There has been strong interest in understanding and employing THs, TH metabolites, and TH mimetics as lipid-modifying drugs. Summary: THs regulate many processes involved in hepatic TAG and cholesterol metabolism to decrease serum cholesterol and intrahepatic lipid content. TH receptor β analogs designed to have less side effects than the natural hormone are currently being tested in phase II clinical studies for NAFLD and hypercholesterolemia. The TH metabolites, 3,5-diiodo-l-Thyronine (T2) and T1AM (3-iodothyronamine), have different beneficial effects on lipid metabolism compared with triiodothyronine (T3), although their clinical application is still under investigation. Also, prodrugs and glucagon/T3 conjugates have been developed that direct TH to the liver. Conclusions: TH-based therapies show clinical promise for the treatment of NAFLD and hypercholesterolemia. Strategies for limiting side effects of TH are being developed and may enable TH metabolites and analogs to have specific effects in the liver for treatments of these conditions. These liver-specific effects and potential suppression of the hypothalamic/pituitary/thyroid axis raise the issue of monitoring liver-specific markers of TH action to assess clinical efficacy and dosing of these compounds.
Source Title: THYROID
URI: https://scholarbank.nus.edu.sg/handle/10635/226730
ISSN: 10507256
15579077
DOI: 10.1089/thy.2018.0664
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

79
checked on Oct 1, 2022

Page view(s)

39
checked on Oct 6, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.